CD274 and melanoma: In melanoma, in trials investigating nivolumab and pembrolizumab in the advanced/metastatic setting, patients whose tumors displayed the positivity for PD-L1 had a higher response rate and a prolonged survival outcome, however, robust and durable responses to treatment were observed even in a considerable proportion of PD-L1 negative patients (33, 34).